Technical Data
B0902-01C
BD3, Recombinant, Human (beta Defensin-3)
50ug
Molecular Biology Storage: -20CShipping: Blue Ice
Beta-Defensin 3, also known as BD3 and DEFB-3, is a membrane-active cationic peptide that functions in inflammation and innate immune responses. There are at least 30 beta-Defensins which are distinguished from alpha-Defensins by the connectivity pattern of their three intramolecular disulfide bonds (1). The 45 aa mature human BD3 shares 38% and 33% aa sequence identity with mouse and rat BD3, respectively (2, 3). It shares 18%-36% aa sequence identity with other human beta-Defensins. BD3 is widely expressed among epithelial tissues, notably by keratinocytes and airway epithelial cells. It is upregulated in response to proinflammatory cytokines, microbial and viral infections, and at the edges of skin wounds (2, 4-6). BD3 induction in osteoarthritis chondrocytes promotes MMP1 and 13 production and inhibits TIMP1 and 2 expression (7). In vivo control of BD3 activity is accomplished in part through cleavage by cathepsins B, L, and S (8). BD3 displays strain specific microbicidal activity toward a broad spectrum of bacteria and yeast (2, 9). BD3 also induces monocyte migration, mast cell activation, and a mast cell-dependent increase in vascular permeability (4, 10). Disruption of the intramolecular disulfide bond pattern in BD3 abrogates its monocyte chemoattractant properties but not its antimicrobial properties (11, 12). BD3 inhibits viral infectivity by interacting directly with HIV-1 plus its coreceptor CXCR4 (5, 13), and with HSV glycoprotein B plus its receptor heparan sulfate (14), and by forming a protective coating on the surface of influenza virus target cells (15).

Source: A DNA sequence encoding the mature human Beta-Defensin 3 (Gly 23-Lys 67; Accession # NP_061131) was expressed in E. coli.

Definition: Measured by its ability to promote internalization of cell surface CXCR4 on the Jurkat human T cell-line.

Applications:
Suitable for use in Western Blot. and Flow Cytometry. Other applications not tested.

Recommended Dilution:
Flow Cytometry: As determined by flow cytometric analysis, the effect is typically a 2-3 fold reduction in fluorescence intensity of Jurkat cells stained with a CXCR4 antibody following a 2 hour pre-treatment with 10ug/ml human Beta-Defensin 3 compared to untreated cells.
Western Blot: 5.2kD SDS-PAGE under reducing conditions.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile acetic acid and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
5.2kD
Source: Recombinant Human
Purity: 95%, as determined by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin 1EU.
Concentration: As reported
Form: Supplied as a lyophilied powder in 30% acetonitrile and 0.1% TFA. Reconstitute with sterile 10mM acetic acid to > 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Dhople, V. et al., 2006, Biochim. Biophys. Acta 1758:1499. 9. Joly, S. et al., 2004, J. Clin. Microbiol. 42:1024.
2. Harder, J. et al., 2001, J. Biol. Chem. 276:5707. 10. Chen, X. et al., 2007, Eur. J. Immunol. 37:434.
3. Schibli, D.J. et al., 2002, J. Biol. Chem. 277:8279. 11. Kluver, E. et al., 2005, Biochemistry 44:9804.
4. Garcia, J.-R.C. et al., 2001, Cell Tissue Res. 306:257. 12. Wu, Z. et al., 2003, Proc. Natl. Acad. Sci. 100:8880.
5. Quinones-Mateu, M.E. et al., 2003, AIDS 17:F39. 13. Feng, Z. et al., 2006, J. Immunol. 177:782.
6. Sorensen, O.E. et al., 2006, J. Clin. Invest. 116:1878. 14. Hazrati, E. et al., 2006, J. Immunol. 177:8658.
7. Varoga, D. et al., 2005, Arthritis Rheum. 52:1736. 15. Leikina, E. et al., 2005, Nat. Immunol. 6:995.
8. Taggart, C.C. et al., 2003, J. Immunol. 171:931.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.